Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?

• Pharvaris recently reported that a Pharvaris-funded analysis of the multinational Adelphi Real World HAE Disease Specific Programme, covering 1,131 patients and 225 physicians across the US, Europe, and Japan, has been published in Advances in Therapy, highlighting real-world hereditary angioedema management patterns and persistent gaps versus guideline-based care.

• The study underscores how factors such as route of administration, portability, treatment burden, and patient perceptions of attack severity strongly influence whether hereditary angioedema patients use on-demand therapies or switch long-term prophylaxis, with daily oral options emerging as a preferred format over injectable regimens.

• We will now explore how these real-world insights on oral preference, treatment burden, and unmet hereditary angioedema needs may shape Pharvaris' investment narrative.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early.

Pharvaris Investment Narrative Recap

To own Pharvaris, you need to believe that oral deucrictibant can win a meaningful share of hereditary angioedema care across both on demand and prophylaxis settings, and that the company can manage its current losses while moving toward commercialization. The new Adelphi real world analysis reinforces the appeal of daily oral treatment and convenience, but does not materially change the near term focus on U.S. regulatory milestones and the risk of further cash burn or potential dilution.

The Adelphi HAE dataset publication connects most directly with Pharvaris' recent CHAPTER 3 Phase 3 success in once daily deucrictibant XR, which already targets oral prophylaxis as a core catalyst. Together, they frame a consistent story around patient preference for oral regimens and treatment usability, factors that could influence how regulators, physicians, and payers view the role of deucrictibant across acute and preventive use as filings progress through 2027.

However, set against this positive real world backdrop, investors should still be aware of the risk that regulatory timing slips or higher than expected cash needs could...

Read the full narrative on Pharvaris (it's free!)

Pharvaris' narrative projects €317.3 million revenue and €32.4 million earnings by 2029. This implies an earnings increase of about €203 million from -€170.9 million today.

Uncover how Pharvaris' forecasts yield a $57.33 fair value , a 81% upside to its current price.